Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT04131686) involved people being treated at either "Control Sites" or "Test Sites" — 146 people started in the Control group and 148 in the Test group. The vast majority completed the study: 138 in the Control group and 143 in the Test group. The trial was measuring changes in sinus-related symptoms — specifically nasal congestion, nasal or post-nasal discharge, facial pain or pressure, and reduced or lost sense of smell — as rated by an investigator (a clinician, not the patient themselves). Each symptom was scored from 0 (no symptom) to 3 (severe), giving a total possible score ranging from 0 to 12, with higher numbers meaning worse symptoms. The reported data shows that both groups had a reduction in their total symptom score between the start of the study (Day 0) and Day 14. The Control group's average total score dropped by 4.37 points, while the Test group's average total score dropped by 3.56 points. A lower (more negative) number here means a bigger reduction in reported symptoms over that two-week period. No other outcome measures — such as secondary outcomes — appear to have been submitted in the data provided, so those figures were not reported and cannot be described here. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Chronic Rhinosinusitis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must be willing to take part and sign a written consent form agreeing to the use of your personal information.
- You must be 18 years old or older (male or female).
- You must have sinus and nasal symptoms that fit one of these patterns: symptoms lasting more than 1 week but less than 12 weeks; OR sinus infections that have come back 3 or more times within 6 months; OR long-term sinus problems (lasting 12 weeks or more) that have recently gotten worse — and in all cases, you must have at least 2 symptoms, including at least one of: a blocked nose OR nasal/post-nasal drip.
- A doctor must rate your overall symptom severity at 4 or above on a scale that scores four symptoms (blocked nose, nasal discharge, facial pain/pressure, and reduced/lost sense of smell) from 0 (none) to 3 (severe).
- You must have had a nasal examination (either a basic visual check or a camera examination), showing at least one of the following: redness, swelling or blockage mainly in the middle of the nose, thick or discoloured mucus mainly in the middle of the nose, or nasal polyps.
Who may not be able to join:
- People whose sinus problems are caused by a dental (tooth or gum) issue.
- People with known long-term lung conditions, such as asthma or chronic bronchitis.
- People whose nasal blockage is so severe that using a nasal spray or inhaled medication would be very difficult.
- People who have had endoscopic sinus surgery within the last 3 months.
- People who have had an allergic reaction to N-acetylcysteine (an inhaled medication used in this trial) or are thought to be at risk of one (confirm with trial site).
- People who are currently pregnant or breastfeeding.
- People who are already taking part in another clinical trial for a drug or medical device, or who plan to join one during this study.
- People whom the study doctor considers unsuitable for participation for any other reason (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in the Total Score of the Investigator's Symptomatic Severity Assessment (Day 0, Day 14)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.